

Alan H Bryce

List of Publications by Citations

Source: <https://exaly.com/author-pdf/2493522/alan-h-bryce-publications-by-citations.pdf>

Version: 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

152
papers

17,872
citations

49
h-index

133
g-index

170
ext. papers

26,217
ext. citations

8.6
avg, IF

5.18
L-index

#	Paper	IF	Citations
152	Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. <i>Lancet Oncology, The</i> , 2015 , 16, 375-84	21.7	1881
151	The Immune Landscape of Cancer. <i>Immunity</i> , 2018 , 48, 812-830.e14	32.3	1754
150	The Molecular Taxonomy of Primary Prostate Cancer. <i>Cell</i> , 2015 , 163, 1011-25	56.2	1713
149	Oncogenic Signaling Pathways in The Cancer Genome Atlas. <i>Cell</i> , 2018 , 173, 321-337.e10	56.2	1124
148	An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics. <i>Cell</i> , 2018 , 173, 400-416.e11	56.2	1072
147	Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer. <i>Cell</i> , 2018 , 173, 291-304.e6	56.2	888
146	Comprehensive Characterization of Cancer Driver Genes and Mutations. <i>Cell</i> , 2018 , 173, 371-385.e18	56.2	854
145	Machine Learning Identifies Stemness Features Associated with Oncogenic Dedifferentiation. <i>Cell</i> , 2018 , 173, 338-354.e15	56.2	560
144	Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas. <i>Cell Reports</i> , 2018 , 23, 239-254.e6	10.6	405
143	Genomic and Functional Approaches to Understanding Cancer Aneuploidy. <i>Cancer Cell</i> , 2018 , 33, 676-689.e3	24.3	377
142	Spatial Organization and Molecular Correlation of Tumor-Infiltrating Lymphocytes Using Deep Learning on Pathology Images. <i>Cell Reports</i> , 2018 , 23, 181-193.e7	10.6	366
141	Pathogenic Germline Variants in 10,389 Adult Cancers. <i>Cell</i> , 2018 , 173, 355-370.e14	56.2	342
140	Comprehensive Analysis of Alternative Splicing Across Tumors from 8,705 Patients. <i>Cancer Cell</i> , 2018 , 34, 211-224.e6	24.3	327
139	Scalable Open Science Approach for Mutation Calling of Tumor Exomes Using Multiple Genomic Pipelines. <i>Cell Systems</i> , 2018 , 6, 271-281.e7	10.6	320
138	Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA. <i>Annals of Oncology</i> , 2020 , 31, 745-759	10.3	303
137	The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma. <i>Cell Reports</i> , 2018 , 23, 313-326.e5	10.6	295
136	A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers. <i>Cancer Cell</i> , 2018 , 33, 690-705.e9	24.3	277

135	lncRNA Epigenetic Landscape Analysis Identifies EPIC1 as an Oncogenic lncRNA that Interacts with MYC and Promotes Cell-Cycle Progression in Cancer. <i>Cancer Cell</i> , 2018 , 33, 706-720.e9	24.3	275
134	Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma. <i>PLoS Genetics</i> , 2014 , 10, e1004135	6	239
133	Driver Fusions and Their Implications in the Development and Treatment of Human Cancers. <i>Cell Reports</i> , 2018 , 23, 227-238.e3	10.6	235
132	Comparative Molecular Analysis of Gastrointestinal Adenocarcinomas. <i>Cancer Cell</i> , 2018 , 33, 721-735.e8	24.3	228
131	Integrated Molecular Characterization of Testicular Germ Cell Tumors. <i>Cell Reports</i> , 2018 , 23, 3392-3406	10.6	200
130	Somatic Mutational Landscape of Splicing Factor Genes and Their Functional Consequences across 33 Cancer Types. <i>Cell Reports</i> , 2018 , 23, 282-296.e4	10.6	188
129	Perspective on Oncogenic Processes at the End of the Beginning of Cancer Genomics. <i>Cell</i> , 2018 , 173, 305-320.e10	56.2	166
128	Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a or Gene Alteration. <i>Journal of Clinical Oncology</i> , 2020 , 38, 3763-3772	2.2	164
127	Pan-cancer Alterations of the MYC Oncogene and Its Proximal Network across the Cancer Genome Atlas. <i>Cell Systems</i> , 2018 , 6, 282-300.e2	10.6	159
126	Comprehensive Molecular Characterization of the Hippo Signaling Pathway in Cancer. <i>Cell Reports</i> , 2018 , 25, 1304-1317.e5	10.6	152
125	Pan-Cancer Analysis of lncRNA Regulation Supports Their Targeting of Cancer Genes in Each Tumor Context. <i>Cell Reports</i> , 2018 , 23, 297-312.e12	10.6	147
124	Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous Carcinomas. <i>Cell Reports</i> , 2018 , 23, 194-212.e6	10.6	146
123	Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 Study. <i>Clinical Cancer Research</i> , 2020 , 26, 2487-2496	12.9	137
122	A Pan-Cancer Analysis of Enhancer Expression in Nearly 9000 Patient Samples. <i>Cell</i> , 2018 , 173, 386-399.e12	56.2	133
121	Systematic Analysis of Splice-Site-Creating Mutations in Cancer. <i>Cell Reports</i> , 2018 , 23, 270-281.e3	10.6	121
120	Molecular Characterization and Clinical Relevance of Metabolic Expression Subtypes in Human Cancers. <i>Cell Reports</i> , 2018 , 23, 255-269.e4	10.6	112
119	PD-1 and PD-L1 Expression in Renal Cell Carcinoma with Sarcomatoid Differentiation. <i>Cancer Immunology Research</i> , 2015 , 3, 1303-7	12.5	106
118	Peripheral blood stem cell transplant for POEMS syndrome is associated with high rates of engraftment syndrome. <i>European Journal of Haematology</i> , 2008 , 80, 397-406	3.8	104

117	A Pan-Cancer Analysis Reveals High-Frequency Genetic Alterations in Mediators of Signaling by the TGF- β Superfamily. <i>Cell Systems</i> , 2018 , 7, 422-437.e7	10.6	85
116	Translocation t(11;14) and survival of patients with light chain (AL) amyloidosis. <i>Haematologica</i> , 2009 , 94, 380-6	6.6	80
115	Evaluation of pre-analytical factors affecting plasma DNA analysis. <i>Scientific Reports</i> , 2018 , 8, 7375	4.9	71
114	Differential Response to Olaparib Treatment Among Men with Metastatic Castration-resistant Prostate Cancer Harboring BRCA1 or BRCA2 Versus ATM Mutations. <i>European Urology</i> , 2019 , 76, 452-458	10.2	69
113	Machine Learning Detects Pan-cancer Ras Pathway Activation in The Cancer Genome Atlas. <i>Cell Reports</i> , 2018 , 23, 172-180.e3	10.6	66
112	-Altered Prostate Cancer: Clinical Features and Therapeutic Outcomes to Standard Systemic Therapies, Poly (ADP-Ribose) Polymerase Inhibitors, and PD-1 Inhibitors. <i>JCO Precision Oncology</i> , 2020 , 4, 370-381	3.6	66
111	Integrated Genomic Analysis of the Ubiquitin Pathway across Cancer Types. <i>Cell Reports</i> , 2018 , 23, 213-226.e3	10.6	56
110	Natural history and therapy of 66 patients with mixed cryoglobulinemia. <i>American Journal of Hematology</i> , 2006 , 81, 511-8	7.1	53
109	Comparison of Universal Genetic Testing vs Guideline-Directed Targeted Testing for Patients With Hereditary Cancer Syndrome. <i>JAMA Oncology</i> , 2021 , 7, 230-237	13.4	53
108	Development and clinical utility of abiraterone acetate as an androgen synthesis inhibitor. <i>Clinical Pharmacology and Therapeutics</i> , 2012 , 91, 101-8	6.1	52
107	Pilot evaluation of PD-1 inhibition in metastatic cancer patients with a history of liver transplantation: the Mayo Clinic experience. <i>Journal of Gastrointestinal Oncology</i> , 2018 , 9, 1054-1062	2.8	51
106	Targeting TMPRSS2 in SARS-CoV-2 Infection. <i>Mayo Clinic Proceedings</i> , 2020 , 95, 1989-1999	6.4	48
105	Implementing individualized medicine into the medical practice. <i>American Journal of Medical Genetics, Part C: Seminars in Medical Genetics</i> , 2014 , 166C, 15-23	3.1	46
104	Preliminary results from the TRITON2 study of rucaparib in patients (pts) with DNA damage repair (DDR)-deficient metastatic castration-resistant prostate cancer (mCRPC): Updated analyses. <i>Annals of Oncology</i> , 2019 , 30, v327-v328	10.3	43
103	A prospective genome-wide study of prostate cancer metastases reveals association of wnt pathway activation and increased cell cycle proliferation with primary resistance to abiraterone acetate-prednisone. <i>Annals of Oncology</i> , 2018 , 29, 352-360	10.3	42
102	Experience with precision genomics and tumor board, indicates frequent target identification, but barriers to delivery. <i>Oncotarget</i> , 2017 , 8, 27145-27154	3.3	40
101	Factors Associated With Survival Following Radium-223 Treatment for Metastatic Castration-resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2017 , 15, e969-e975	3.3	35
100	Radiographic progression with nonrising PSA in metastatic castration-resistant prostate cancer: post hoc analysis of PREVAIL. <i>Prostate Cancer and Prostatic Diseases</i> , 2017 , 20, 221-227	6.2	34

99	Preliminary results from TRITON2: A phase II study of rucaparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination repair (HRR) gene alterations. <i>Annals of Oncology</i> , 2018 , 29, viii272	10.3	29
98	Clinical activity of pembrolizumab in metastatic prostate cancer with microsatellite instability high (MSI-H) detected by circulating tumor DNA 2020 , 8,		25
97	Determining the frequency of pathogenic germline variants from exome sequencing in patients with castrate-resistant prostate cancer. <i>BMJ Open</i> , 2016 , 6, e010332	3	25
96	Response to rituximab in patients with type II cryoglobulinemia. <i>Clinical Lymphoma and Myeloma</i> , 2006 , 7, 140-4		23
95	Pilot Trial of Selecting Molecularly Guided Therapy for Patients with Non-V600 BRAF-Mutant Metastatic Melanoma: Experience of the SU2C/MRA Melanoma Dream Team. <i>Molecular Cancer Therapeutics</i> , 2015 , 14, 1962-71	6.1	20
94	Clinical Implementation of Integrated Genomic Profiling in Patients with Advanced Cancers. <i>Scientific Reports</i> , 2016 , 6, 25	4.9	20
93	Current Imaging Techniques for and Imaging Spectrum of Prostate Cancer Recurrence and Metastasis: A Pictorial Review. <i>Radiographics</i> , 2020 , 40, 709-726	5.4	19
92	Androgen receptor splice variant 7 in castration-resistant prostate cancer: Clinical considerations. <i>International Journal of Urology</i> , 2016 , 23, 646-53	2.3	17
91	Phase I study of temsirolimus in combination with EKB-569 in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2012 , 30, 1934-41	4.3	16
90	Therapy With Lu-DOTATATE: Clinical Implementation and Impact on Care of Patients With Neuroendocrine Tumors. <i>American Journal of Roentgenology</i> , 2019 , 213, 309-317	5.4	15
89	Pertuzumab plus trastuzumab for HER2-positive metastatic urothelial cancer (mUC): Preliminary data from MyPathway.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 348-348	2.2	14
88	Clonal analyses of refractory testicular germ cell tumors. <i>PLoS ONE</i> , 2019 , 14, e0213815	3.7	13
87	Simultaneous characterization of somatic events and HPV-18 integration in a metastatic cervical carcinoma patient using DNA and RNA sequencing. <i>International Journal of Gynecological Cancer</i> , 2014 , 24, 329-38	3.5	13
86	NCCTG N0879 (Alliance): A randomized phase 2 cooperative group trial of carboplatin, paclitaxel, and bevacizumab ± everolimus for metastatic melanoma. <i>Cancer</i> , 2018 , 124, 537-545	6.4	12
85	A novel report of cig-FISH and cytogenetics in POEMS syndrome. <i>American Journal of Hematology</i> , 2008 , 83, 840-1	7.1	12
84	Phase 1 trial of Vismodegib and Erlotinib combination in metastatic pancreatic cancer. <i>Pancreatology</i> , 2020 , 20, 101-109	3.8	12
83	A Living, Interactive Systematic Review and Network Meta-analysis of First-line Treatment of Metastatic Renal Cell Carcinoma. <i>European Urology</i> , 2021 , 80, 712-723	10.2	12
82	Tumor Frameshift Mutation Proportion Predicts Response to Immunotherapy in Mismatch Repair-Deficient Prostate Cancer. <i>Oncologist</i> , 2021 , 26, e270-e278	5.7	12

81	Genomic medicine and incidental findings: balancing actionability and patient autonomy. <i>Mayo Clinic Proceedings</i> , 2014 , 89, 718-21	6.4	11
80	Assessment of clinical outcomes with immune checkpoint inhibitor therapy in melanoma patients with CDKN2A and TP53 pathogenic mutations. <i>PLoS ONE</i> , 2020 , 15, e0230306	3.7	10
79	Vemurafenib-associated gingival hyperplasia in patient with metastatic melanoma. <i>Journal of the American Academy of Dermatology</i> , 2014 , 71, e205-6	4.5	10
78	TRITON3: An international, randomized, open-label, phase III study of the PARP inhibitor rucaparib vs. physician choice of therapy for patients with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination deficiency (HRD).. <i>Journal of Clinical Oncology</i> , 2018 , 36, TPS389-TPS389	2.2	10
77	Alternative Outpatient Chemotherapy Scheduling Method to Improve Patient Service Quality and Nurse Satisfaction. <i>Journal of Oncology Practice</i> , 2018 , 14, e82-e91	3.1	10
76	TRITON2: An international, multicenter, open-label, phase II study of the PARP inhibitor rucaparib in patients with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination deficiency (HRD).. <i>Journal of Clinical Oncology</i> , 2018 , 36, TPS388-TPS388	2.2	9
75	A Multidisciplinary Biospecimen Bank of Renal Cell Carcinomas Compatible with Discovery Platforms at Mayo Clinic, Scottsdale, Arizona. <i>PLoS ONE</i> , 2015 , 10, e0132831	3.7	8
74	Comparison of germline mutations in African American and Caucasian men with metastatic prostate cancer. <i>Prostate</i> , 2021 , 81, 433-439	4.2	8
73	Impact of timing of administration of bone supportive therapy on pain palliation from radium-223. <i>Cancer Treatment and Research Communications</i> , 2019 , 18, 100114	2	8
72	Review: Mathematical Modeling of Prostate Cancer and Clinical Application. <i>Applied Sciences (Switzerland)</i> , 2020 , 10, 2721	2.6	8
71	A multicenter phase I study of cabazitaxel, mitoxantrone, and prednisone for chemotherapy-naïve patients with metastatic castration-resistant prostate cancer: A department of defense prostate cancer clinical trials consortium study. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017 , 35, 149.e7-149.e13	2.8	7
70	Systemic treatment for metastatic castrate resistant prostate cancer: Does sequence matter?. <i>Prostate</i> , 2020 , 80, 399-406	4.2	7
69	Stroke detection with 3 different PET tracers. <i>Radiology Case Reports</i> , 2019 , 14, 1447-1451	1	7
68	Mutational Profile in Vulvar, Vaginal, and Urethral Melanomas: Review of 37 Cases With Focus on Primary Tumor Site. <i>International Journal of Gynecological Pathology</i> , 2020 , 39, 587-594	3.2	7
67	How We Do It: A Multidisciplinary Approach to Lu DOTATATE Peptide Receptor Radionuclide Therapy. <i>Radiology</i> , 2021 , 298, 261-274	20.5	7
66	A Study of Combination Bicalutamide and Raloxifene for Patients With Castration-Resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2017 , 15, 196-202.e1	3.3	6
65	Intermittent BRAF Inhibition Can Achieve Prolonged Disease Control in BRAF Mutant Melanoma. <i>Cureus</i> , 2015 , 7, e410	1.2	6
64	Janus Kinase Inhibitors and Risk of Venous Thromboembolism: A Systematic Review and Meta-analysis. <i>Mayo Clinic Proceedings</i> , 2021 , 96, 1861-1873	6.4	6

63	CDK12-altered prostate cancer: Clinical features and therapeutic outcomes to standard systemic therapies, PARP inhibitors, and PD1 inhibitors. <i>Annals of Oncology</i> , 2019 , 30, v326-v327	10.3	5
62	Phase II trial of oral topotecan and intravenous carboplatin with G-CSF support in previously untreated patients with extensive stage small cell lung cancer: A North Central Cancer Treatment Group Study. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2010 , 33, 353-7	2.7	5
61	Genomic characteristics associated with clinical activity of rucaparib in patients (pts) with BRCA1 or BRCA2 (BRCA)-mutated metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2020 , 38, 178-178	2.2	4
60	Unusual manifestations of diffuse-type tenosynovial giant cell tumor in two patients: importance of radiologic-pathologic correlation. <i>Skeletal Radiology</i> , 2020 , 49, 483-489	2.7	4
59	PT-112: A well-tolerated novel immunogenic cell death (ICD) inducer with activity in advanced solid tumors. <i>Annals of Oncology</i> , 2018 , 29, viii143	10.3	4
58	FOXA1 overexpression suppresses interferon signaling and immune response in cancer. <i>Journal of Clinical Investigation</i> , 2021 , 131,	15.9	4
57	Association of Concomitant Bone Resorption Inhibitors With Overall Survival Among Patients With Metastatic Castration-Resistant Prostate Cancer and Bone Metastases Receiving Abiraterone Acetate With Prednisone as First-Line Therapy. <i>JAMA Network Open</i> , 2021 , 4, e2116536	10.4	4
56	A phase I/II study of rovalpituzumab tesirine in delta-like 3-expressing advanced solid tumors. <i>Npj Precision Oncology</i> , 2021 , 5, 74	9.8	4
55	Shared and unique genomic structural variants of different histological components within testicular germ cell tumours identified with mate pair sequencing. <i>Scientific Reports</i> , 2019 , 9, 3586	4.9	3
54	PANDA: pathway and annotation explorer for visualizing and interpreting gene-centric data. <i>PeerJ</i> , 2015 , 3, e970	3.1	3
53	Patterns of Cancer Progression of Metastatic Hormone-sensitive Prostate Cancer in the ECOG3805 CHARTED Trial. <i>European Urology Oncology</i> , 2020 , 3, 717-724	6.7	3
52	Catechol-Based Functionalizable Ligands for Gallium-68 Positron Emission Tomography Imaging. <i>Inorganic Chemistry</i> , 2020 , 59, 12025-12038	5.1	3
51	Identifying treatment options for BRAFV600 wild-type metastatic melanoma: A SU2C/MRA genomics-enabled clinical trial. <i>PLoS ONE</i> , 2021 , 16, e0248097	3.7	3
50	Response to Rucaparib in BRCA-Mutant Metastatic Castration-Resistant Prostate Cancer Identified by Genomic Testing in the TRITON2 Study. <i>Clinical Cancer Research</i> , 2021 ,	12.9	3
49	Molecular Modeling and Functional Analysis of Exome Sequencing-Derived Variants of Unknown Significance Identify a Novel, Constitutively Active FGFR2 Mutant in Cholangiocarcinoma. <i>JCO Precision Oncology</i> , 2017 , 2017,	3.6	2
48	Results of a multicenter phase I/II trial of abiraterone acetate plus BEZ235 in metastatic, castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2014 , 32, e16042-e16042	2.2	2
47	A phase I study of PT-112 in advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 2519-2519	2.2	2
46	Patterns of PSA versus clinically progressive disease in the E3805 CHARTED trial.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 5046-5046	2.2	2

45	Hypoxia-Activated Alkylating Agents in BRCA1-Mutant Ovarian Serous Carcinoma. <i>Cureus</i> , 2017 , 9, e15171.2	2	2
44	Evaluation of pre-analytical factors affecting plasma DNA analysis		2
43	Assessment of isochromosome 12p and 12p abnormalities in germ cell tumors using fluorescence in situ hybridization, single-nucleotide polymorphism arrays, and next-generation sequencing/mate-pair sequencing. <i>Human Pathology</i> , 2021 , 112, 20-34	3.7	2
42	Differential Activity of PARP Inhibitors in - Versus -Altered Metastatic Castration-Resistant Prostate Cancer. <i>JCO Precision Oncology</i> , 2021 , 5,	3.6	2
41	Comprehensive Genomic Analysis of Metastatic Mucinous Urethral Adenocarcinoma Guides Precision Oncology Treatment: Targetable EGFR Amplification Leading to Successful Treatment With Erlotinib. <i>Clinical Genitourinary Cancer</i> , 2017 , 15, e727-e734	3.3	1
40	Current status and future directions of personalized medicine. <i>Genome Medicine</i> , 2013 , 5, 62	14.4	1
39	14q32 Abnormalities and 13q Deletions Are Common in Primary Systemic Amyloidosis Using Cytoplasmic Immunoglobulin Fluorescence In Situ Hybridization (cIg-FISH).. <i>Blood</i> , 2007 , 110, 2477-2477	2.2	1
38	Association of androgen receptor V9 (ARV9) mRNA expression in metastatic tissue with early resistance to pre-chemotherapy abiraterone acetate/prednisone (AA/P).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 237-237	2.2	1
37	Assessment of treatment response to immunotherapy in melanoma patients with pathogenic mutations of NRAS, BRAF, CDKN2A and P53.. <i>Journal of Clinical Oncology</i> , 2017 , 35, e21057-e21057	2.2	1
36	Pilot evaluation of PD-1 inhibition in metastatic cancer patients with liver transplantations (LT): The Mayo Clinic experience.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 328-328	2.2	1
35	Evolving natural history of metastatic prostate cancer.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 5063-5063	2.2	1
34	Evolving Natural History of Metastatic Prostate Cancer. <i>Cureus</i> , 2020 , 12, e11484	1.2	1
33	Genomic profiling proves metastasis of cutaneous melanoma to vitreal fluid. <i>Melanoma Research</i> , 2020 , 30, 590-593	3.3	1
32	Genome-wide analysis of metastases to reveal association of pathway activation with abiraterone acetate/prednisone (AA/P) primary resistance and cell cycle proliferation pathway activation with response duration in metastatic castrate resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2017 , 35, 5053-5053	2.2	1
31	Impact of timing of administration of bone supportive therapy on pain palliation from radium-223.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 5023-5023	2.2	1
30	Analysis of fragment ends in plasma DNA from patients with cancer		1
29	Differential impact of tumor suppressor gene (TP53, PTEN, RB1) alterations and treatment outcomes in metastatic, hormone-sensitive prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2021 ,	6.2	1
28	Quantifying Absolute Benefit for Adjuvant Treatment Options in Renal Cell Carcinoma: A Living Interactive Systematic Review and Network Meta-analysis.. <i>Critical Reviews in Oncology/Hematology</i> , 2022 , 103706	7	1

27	Cancer Genomics and Evolution 2017 , 1-27		0
26	Twitter Use by Academic Nuclear Medicine Programs: Pilot Content Analysis Study. <i>JMIR Formative Research</i> , 2021 , 5, e24448	2.5	0
25	Prognostic role of 11C-choline PET/CT scan in patients with metastatic castrate resistant prostate cancer undergoing primary docetaxel chemotherapy. <i>Prostate</i> , 2022 , 82, 41-48	4.2	0
24	Focus on Transitional Disease: A Critical Interval to Delay Progression of Prostate Cancer. <i>Oncology</i> , 2021 , 35, 166	1.8	0
23	Outcomes of COVID-19 in Patients With Cancer: A Closer Look at Pre-Emptive Routine Screening Strategies. <i>JCO Oncology Practice</i> , 2021 , 17, e1382-e1393	2.3	0
22	Guidelines for Management of Treatment-Emergent Adverse Events During Rucaparib Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer.. <i>Cancer Management and Research</i> , 2022 , 14, 673-686	3.6	0
21	The Mayo Clinic Experience with 66 Patients with Type II Cryoglobulinemia.. <i>Blood</i> , 2004 , 104, 1493-1493	2.2	0
20	Response to Rituximab in Type II Cryoglobulinemia.. <i>Blood</i> , 2005 , 106, 3499-3499	2.2	0
19	Engraftment Syndrome Is Common in Patients with POEMS Syndrome Undergoing PBSCT.. <i>Blood</i> , 2007 , 110, 2995-2995	2.2	0
18	A multicenter phase I study of cabazitaxel, mitoxantrone, and prednisone for chemotherapy-naive patients with metastatic castration-resistant prostate cancer.. <i>Journal of Clinical Oncology</i> , 2014 , 32, e16060-e16060	2.2	0
17	Androgen receptor (AR) based biomarker association with response to abiraterone acetate/prednisone (AA/P) in metastatic castrate resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2015 , 33, 174-174	2.2	0
16	Feasibility analysis of pathology and genetic yield from a prospective trial of tissue biopsies in metastatic castrate-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2015 , 33, 249-249	2.2	0
15	Effect of metastatic site biopsy on circulating tumor cell (CTC) count in castrate resistant prostate cancer (CRPC) stage.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 190-190	2.2	0
14	The role of highly selective androgen receptor (AR) targeted therapy in men with biochemically relapsed hormone sensitive prostate cancer.. <i>Journal of Clinical Oncology</i> , 2015 , 33, TPS5084-TPS5084	2.2	0
13	A molecular and clinico-pathological model for predicting abiraterone acetate/prednisone (AA/P) efficacy in metastatic castrate resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2015 , 33, 5056-5056	2.2	0
12	Intermittent abiraterone-acetate administration protocol and prognosis prediction for castrate-resistant prostate cancer.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 353-353	2.2	0
11	Association of androgen receptor variant 9 (AR-V9) mRNA expression levels in metastatic tissue with resistance to abiraterone acetate/prednisone (AA/P).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 5036-5036	2.2	0
10	Predictors for survival after radium-223 (R223) treatment for castration-resistant metastatic prostate cancer.. <i>Journal of Clinical Oncology</i> , 2016 , 34, e16521-e16521	2.2	0

- 9 Impact of pharmacist-led monitoring of olaparib (O) for metastatic castrate resistant prostate cancer (mCRPC).. *Journal of Clinical Oncology*, **2017**, 35, e569-e569 2.2
- 8 A study of real-time CLIA-enabled whole genome tumor sequencing: Results for testicular cancer and sarcomatoid RCC.. *Journal of Clinical Oncology*, **2014**, 32, 463-463 2.2
- 7 A multicenter phase I study of cabazitaxel (Cbz), mitoxantrone (Mito), and prednisone (Pred) (CAMP) for chemotherapy-naive patients with metastatic castration-resistant prostate cancer (mCRPC).. *Journal of Clinical Oncology*, **2014**, 32, 243-243 2.2
- 6 Genome-wide profiling of histone 3 lysine 36 trimethylation in clear cell renal cell carcinoma.. *Journal of Clinical Oncology*, **2014**, 32, 464-464 2.2
- 5 Shining a warm light on cryoglobulinemia. *Oncology*, **2013**, 27, 1116, 1118 1.8
- 4 Assessment of clinical outcomes with immune checkpoint inhibitor therapy in melanoma patients with CDKN2A and TP53 pathogenic mutations **2020**, 15, e0230306
- 3 Assessment of clinical outcomes with immune checkpoint inhibitor therapy in melanoma patients with CDKN2A and TP53 pathogenic mutations **2020**, 15, e0230306
- 2 Assessment of clinical outcomes with immune checkpoint inhibitor therapy in melanoma patients with CDKN2A and TP53 pathogenic mutations **2020**, 15, e0230306
- 1 Assessment of clinical outcomes with immune checkpoint inhibitor therapy in melanoma patients with CDKN2A and TP53 pathogenic mutations **2020**, 15, e0230306